Getting to Zero: On the Verge of Polio Eradication. Ellyn Ogden, MPH USAID Worldwide Polio Eradication Coordinator May 17, 2017

Similar documents
宮村参考人提出資料 資料 2-2

Global Polio Eradication & Endgame Strategy. December 2015

Global ProhrammeUpdate?

Global and Regional update on Polio Eradication Activities. Kenya Paediatric Association Pride Inn, Mombasa April 26, 2018

Polio: A Global Update. DCVMN-- Seoul, Korea Simona Zipursky, WHO/HQ/POL September

VPD in Mediterranean Basin and Black Sea: the Polio case

Global Overview Polio Partners Group, December Note: Gavi requirements of $122.2 million are not included in this slide

Development of the Polio Eradication and Endgame Strategic plan

Wild Poliovirus*, 03 Aug 2004 to 02 Aug 2005

Poliovirus : éradication pour les prochaines JNI?

Programme Update. Transition Independent Monitoring Board London, 2 November Geneva, 23 October 2017

Wild Poliovirus Weekly Update

Status of Outbreak Vulnerable Countries

POLIO ERADICATION AND POST-CERTIFICATION STRATEGY

Polio Eradication and Endgame Strategy

CDC ASSESSMENT OF RISKS TO THE GLOBAL POLIO ERADICATION INITIATIVE (GPEI) STRATEGIC PLAN

Global Polio Eradication, Progress, Impact of Ebola, Risks & Opportunities. Polio Partners Group 8 December 2014

Update on Progress and Challenges in Achieving Measles and Rubella Targets

Prioritizing Emergency Polio Eradication Activities

Wild poliovirus type 1 and Circulating vaccine-derived poliovirus cases

Media centre Statement on the 7th IHR Emergency Committee meeting regarding the international spread of poliovirus

Market Updates: Routine Vaccine Introductions IPV. Vaccine Industry Consultation October 2018 UNICEF Supply Division

Polio Eradication: Beginning of the End, or End of the Beginning?

Why still Polio Donato Greco ECDC polio consultant 14 April 2016

Pakistan & Afghanistan: Will we soon see the end of polio?

Global Measles and Rubella Update. April 2018

POLIOMYELITIS ERADICATION: PROGRESS REPORT. Information Document CONTENTS BACKGROUND PROGRESS MADE NEXT STEPS... 12

Global Measles and Rubella Update November 2018

AIDA M. SALONGA, MD, FPNA, FCNSP CHAIR, AFP EXPERT PANEL, DOH MEMBER, REGIONAL CERTIFICATION COMMITTEE, WHO

GOAL 2: ACHIEVE RUBELLA AND CRS ELIMINATION. (indicator G2.2) Highlights

The Promise of Introducing Rubella Containing Vaccines on the Impact of Rubella and Measles Control

Poliomyelitis: successful and critical issues in the eradication process

Objective 2 Strengthening Routine Immunization, IPV introduction and the topv-bopv switch

Global Measles and Rubella Update October 2018

Annex 2 A. Regional profile: West Africa

Oral Polio Vaccine Supply Outlook. UNICEF Supply Division

Measles and Rubella Global Update SAGE 19 October 2017

Global reductions in measles mortality and the risk of measles resurgence

TECHNICAL UPDATE: POLIO ERADICATION AND ROUTINE IMMUNIZATION STRENGTHENING. Gavi Board pre-meeting December 9, 2014, Geneva.

Accelerating Emergency Polio Eradication Activities. SAGE, November 6, 2012

Global Update On behalf of the GPEI Michel Zaffran, Director, Polio Eradica9on, World Health Organiza9on DCVMN General Assembly, Buenos Aires, 27

CONTENTS. Paragraphs I. BACKGROUND II. PROGRESS REPORT ON THE AFRICAN REGIONAL IMMUNIZATION STRATEGIC PLAN

11 th Meeting of the SAGE Polio Working Group

Progress report on eradication of poliomyelitis: regional implications of the endgame strategy

Proposed Recommenda.ons for OPV2 Withdrawal: Report from the Polio Working Group. Peter Figueroa Chair, SAGE Working Group April 14, 2014

The Polio Endgame

International PolioPlus Committee PolioPlus Facts and Figures June Rotary s financial contribution to the polio eradication effort:

Polio Eradication in India. Dr Sunil Bahl Deputy Project Manager WHO Country Office for India 28 October 2014

What is this document and who is it for?

FRAMEWORK FOR CERTIFICATION OF POLIO ERADICATION IN THE AFRICAN REGION. Report of the Secretariat EXECUTIVE SUMMARY

Update from GAVI Aurelia Nguyen

ANNEX Page. AFR/RC61/11 4 July 2011 ORIGINAL: ENGLISH REGIONAL COMMITTEE FOR AFRICA

Revisiting Old and Addressing Current Issues on Vaccines: POLIO

The switch from trivalent to bivalent oral polio vaccine. 18 th December, 2015

Measles and Rubella Global Update SAGE April 2018

OVERVIEW OF THE POLIO ERADICATION AND ENDGAME STRATEGIC PLAN AND THE topv TO bopv SWITCH

IMMUNIZATION VACCINES & EMERGENCIES

Overview of the Polio Country Situation

Meeting of the Polio Oversight Board (call) 1 September :00 am 11:00 am Meeting Minutes

Global Polio Eradication Initiative

Summary of findings, decisions and recommendations

POLIO ERADICATION IN THE AFRICAN REGION: PROGRESS REPORT. Information document EXECUTIVE SUMMARY

Polio Eradication and Surveillance. December

Poliomyelitis eradication in the WHO European Region

Polio Eradication Rotary s Commitment & Global Partnership. Carol Wells District 6440 EPN Chair

Polio Eradication Global update SAGE Meeting, Geneva 17 April Michel Zaffran, Director, Polio Eradication, WHO On Behalf of the GPEI

Progress Towards Global Polio Eradication by 2012: Progress and Ongoing Challenges

TFI Proceedings, Recommendations and implications for 2005

Report of the Polio WG Meeting February Dr. Peter Figueroa Co-Chair, SAGE Polio Working Group 17 April, 2018

Ethics Perspective of Immunisation Programs

Update on Status of Wild Poliovirus Outbreak in Kenya. 9 th Meeting of the IMB 1-3 October 2013 London, UK

THE SITUATION OF YELLOW FEVER IN THE AFRICAN REGION: THE PLAN TO END YF EPIDEMICS IN 2026

Objective 1: Poliovirus detection and interruption

Eradication of poliomyelitis

Report on MCSP Support for the Polio Switch in April 2016

Update on WHO Global Action Plan for containment of polioviruses (GAPIII/ CCS)

KEY ISSUES IN IMMUNIZATION IN AFRICA

Global Polio Partners Group Monitoring Framework for the GPEI Polio Eradication & Endgame Strategic Plan

Update on Polio Vaccine Supply

Vaccines and Biologicals

Table 1. Measles case classification and incidence by country and area, WHO Western Pacific Region,

Polio Eradication Initiative Afghanistan

Summary of findings, decisions and recommendations

511,000 (57% new cases) ~50,000 ~30,000

TECHNICAL ADVISORY GROUP ON POLIO ERADICATION IN THE HORN OF AFRICA. 8-9 February 2012 in Nairobi, Kenya. Executive Summary

Context 4.1 WHERE WE ARE TODAY. Figure 2: Countries with cases of wild poliovirus, 2011 and 2012

Expanded Programme on Immunization (EPI)

WHO/POLIO/ Global. Polio. Progress Department of Vaccines and Biologicals

IMMUNIZATION VACCINE DEVELOPMENT

Foot-and-Mouth Disease Situation Food and Agriculture Organization of the United Nations Monthly Report

The epidemiology of tuberculosis

Comments on this bulletin are welcome. Please to Dr. Mary Agócs

WHO Global Task Force on TB Impact Measurement An overview

POLIO POST-CERTIFICATION STRATEGY. Summary overview 8 August 2017

Preeradication Vaccine Policy Options for Poliovirus Infection and Disease Control

Update on polio vaccine supply & forecast

EBOLA SITUATION REPORT

IEAG Findings 5-6 December 2005

Global Polio Eradication Initiative (GPEI) Status Report

The State of Measles and Rubella in the WHO European Region

Transcription:

Getting to Zero: On the Verge of Polio Eradication Ellyn Ogden, MPH USAID Worldwide Polio Eradication Coordinator May 17, 2017

Polio Eradication and Endgame Strategy 1. Poliovirus detection & interruption 2. OPV2 withdrawal, IPV introduction, immunization system strengthening 3. Containment & Global Certification 4. Transition Planning 2

Progress in WPV eradication 37 Cases in 2016 1988 2016 Public Health Emergency of International Concern declared in May 2014 and reconfirmed every 3 months since that time 5 cases in 2017 (Afghanistan and Pakistan) as of 10 May 2017

Global Wild Poliovirus & cvdpv Cases 1, Previous 6 Months 2 Country Onset of most recent WPV1 case Number of WPV1 cases Number of WPV infected districts Same period 4 Same period Current4 last year 4 Current last year 4 Nigeria 0 0 0 0 0 AFR 0 0 0 0 Pakistan 13-Feb-17 3 17 3 12 Afghanistan 21-Feb-17 4 5 4 4 EMR 21-Feb-17 7 22 7 16 cvdpv current 6 months 2 Number of cases 0 1 0 1 Wild poliovirus type 1 cvdpv type 2 2 Endemic country 1 Excludes viruses detected from environmental surveillance 2 Onset of paralysis 10 November 2016 09 May 2017 Global 21-Feb-17 7 22 7 16 4 Current rolling 6 months: 10 November 2016 09 May 2017 Same period previous year: 10 November 2015 09 May 2016 Data in WHO HQ as of 09 May 2017 1

Pakistan Afghanistan Lowest number of cases ever in the epidemiological block

Pakistan and Afghanistan: Corridors of transmission common reservoirs spanning borders between Afghanistan and Pakistan involving: 1) selected geographic areas, and 2) demographic groups Three main shared transmission corridors/endemic zones: a) Southern/Western (Kandahar & Helmand Quetta) b) Southeast Afghanistan/South KP (Paktika South Waziristan) c) Eastern/Northern (Nangahar & Jalalabad Peshawar Valley) 4 risk scenarios for future WPV transmission due to movement of people, and GPEI action: Movement within reservoir areas Areas with high population movement identified and focused Emphasis on guest children (vaccinators, SMs, Supervisors and monitors) Straddling populations at border areas Mapping of areas and relations on other side of border Inclusion in high risk area for increased focus Nomads Routes, seasonality identified Nomad specific campaigns, Nomad specific PTTs, Inclusion in SNID/NID Returnees Vaccination at border, UNHCR/IOM centers IPV (under 5) and OPV (under 10) Identification of settlement and inclusion in microplan

Inaccessible children: May 2016- Mar 17 400,000 300,000 200,000 100,000 0 May NID Aug NID Oct NID Mar NID2 South & West East North East Rest of Afghanistan Afghanistan Pakistan

Nigeria and Lake Chad

WPV1 and VDPV2 in Nigeria, 2016-2017 2016: 4 WPV1 from Borno. Date of onset of last case August 21, 2016 WPV1 in Borno are orphans and isolated in security compromised areas in northern part of the state 2 cvdpv2 cases both from contacts (Borno and Sokoto). Last case is from Bodinga LGA in Sokoto State with date of onset September 28, 2016 2017: 10 VDPV2 isolates from environmental surveillance sites: 6 in Sokoto 2 in Gombe 1 in Bauchi 1 in Katisna All VDPV2 isolated in 2017 are not circulating by GPEI guidelines 1 VDPV2 was isolated from a healthy contact in Sokoto (50 th Stool sample) Nucleotide changes range from 6-10

THE OUTBREAK LED TO A MASSIVE REGIONALRESPONSE TARGETING 40+ MILLION WITH OPV MULTIPLE TIMES Overall cost of the outbreak Aug-Dec: $140m 1 0

Horn Of Africa

HOA WILD POLIO VIRUS (Type1) OUTBREAKS 2004 to 2013 2016?? 2016?? 2004-2008 Outbreak 2009-2012 Outbreak 2013 Outbreak

Children in inaccessible areas, May 2017 Access status South Sudan Somalia Yemen Sudan Total in HOA Partially accessible 16,282 655,967 363,864 109,222 areas 1,145,335 Completely Inaccessible areas 296,320 Total population U5 in security challenged area 312,602 (compared to 450,000 in 2016) 236,081 (compared to 400,000 in 2016) 892,048 51,972 142,532 415,836 251,754 (compared (compared to 600,000 in to 305867 in 2016) 2016) 726,905 1,872,240 Yemen Somalia Sudan S. Sudan

VDPV Outbreaks

Global Circulating Vaccine-derived Poliovirus Cases 1,2, 2000-2017 cvdpv type 1 3 Country 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Onset of most recent case Laos 8 3 11-Jan-16 Madagascar 1 10 22-Aug-15 Ukraine 2 07-Jul-15 Mozambique 2 02-Jun-11 Myanmar 1 4 06-Dec-07 Indonesia 46 26-Oct-05 China 2 11-Nov-04 Philippines 3 26-Jul-01 DOR/Haiti 12 9 12-Jul-01 Total type 1 12 12 0 0 2 46 1 4 0 0 0 2 0 0 1 20 3 0 cvdpv type 2 3 Country 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Onset of most recent case Pakistan 16 48 22 2 1 17-Dec-16 Nigeria 3 22 71 68 155 27 34 8 4 30 1 1(1 2 ) 28-Oct-16 Guinea 1 7 14-Dec-15 Myanmar 2 05-Oct-15 South Sudan 2 12-Sep-14 Cameroon 4 12-Aug-13 Niger 2 2 1 1 1 11-Jul-13 Chad 1 12 4 12-May-13 Afghanistan 5 1 9 3 13-Mar-13 Somalia 1 6 1 9 1 1 09-Jan-13 Kenya 3 29-Aug-12 DRCongo 13 5 18 11 17 04-Apr-12 China 2 06-Feb-12 Yemen 9 05-Oct-11 India 15 2 18-Jan-10 Ethiopia 3 1 16-Feb-09 Madagascar 1 4 3 13-Jul-05 Total type 2 0 1 4 0 0 6 24 71 85 184 55 65 68 65 55 12 2 0 cvdpv type 3 3 Country 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 Onset of most recent case Yemen 3 1 12-Jul-13 Ethiopia 1 5 17-May-10 Cambodia 1 1 15-Jan-06 Total type 3 0 0 0 0 0 1 1 0 0 1 5 0 3 1 0 0 0 0 Data in WHO HQ as of 09 May 2017 1 For cvdpv definition see http://polioeradication.org/wp-content/uploads/2016/09/reporting-and-classification-of-vdpvs_aug2016_en.pdf. Niger 2006, Niger 2009, Niger 2010, Chad 2010 cvdpvs are linked to the Nigeria outbreak. Kenya 2012 cvdpvs are linked to the Somalia outbreak. Nigeria figures include cases with WPV1/cVDPV2 mixture: 2005-2, 2006-1, 2007-1, 2008-3, 2009-1, 2011-1; WPV3/cVPDV2 mixture 2007-2. 2 In Nigeria, 1 cvdpv2 from a healthy child contact of a WPV1 case not included in country or global case count. 3 Figures include multiple emergences and transmission chains.

Polio Eradication and Endgame Strategy 1. Poliovirus detection & interruption 2. OPV2 withdrawal, IPV introduction, immunization system strengthening 3. Containment & Global Certification 4. Legacy Planning

Transitioning Away from topv in Three Stages 2019-2020 2016 Withdrawal Switch of bopv & 2015-2016 routine OPV use topv to bopv Introduction at least one dose of IPV into routine immunization Ongoing STRENGTHENING of routine immunization services IMG, IPV Introduction and OPV Withdrawal

173 countries using IPV Introduced* to date (173 countries or 89%) Introduction delayed to 2017/2018 (21 countries or 11%) Not available Not applicable * Including partial introduction in India Introduction delayed : Angola, Burkina Faso, Cabo Verde, Egypt, Eritrea, Ghana, Kyrgyzstan, Liberia, Malawi, Mongolia, Republic of Moldova (the), Rwanda, Sierra Leone, Tajikistan, Togo, Turkmenistan, United Republic of Tanzania (the), Uzbekistan, Viet Nam, Zambia, Zimbabwe The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. WHO 2016. All rightsreserved. Data source: WHO/IVB Database, as of 08 December 2016 Map production Immunization Vaccinesand Biologicals (IVB), World Health Organization

Countries with IPV supply disruptions 0 950 1,900 3,800 Kil Countries with delayed introduction (18 countries or 9.2%) Countries with delayed resupply (17 countries or 8.8%) Not available / Countries already introduced Not applicable Data source: WHO/IVB Database, as of 11 April 2017 Map production Immunization Vaccines and Biologicals (IVB), World Health Organization 2 The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. WHO 2016. All rights reserved.

Polio Eradication and Endgame Strategy 1. Poliovirus detection & interruption 2. OPV2 withdrawal, IPV introduction, immunization system strengthening 3. Containment & Global Certification 4. Transition Planning

figure 1: containment requirements Phase I: Preparation for containment of poliovirus type 2 Phase II: Poliovirus type 2 containment period Phase III: Final poliovirus containment Global readiness criteria met OPV2 withdrawal 6 x Regional certification of WPV eradication bopv cessation Poliovirusessential facilities holding WPV Inventory Destruction, Preparation for containment Containment certification IIa: WPV2 containment IIIa: Final containment of all WPV Poliovirusessential facilities holding OPV/Sabin only (no WPV) Destruction, Preparation for containment Containment certification IIb: OPV2/Sabin2 poliovirus containment IIIb:Final containment of all OPV/Sabin polioviruses Poliovirusnon-essential facilities Destruction, Safe handling, No storage Adopt safe measures Safe handling of new samples potentially containing poliovirus material in poliovirus-non-essential laboratories

Global Polio Laboratory Network 146 Laboratories Worldwide b EUR AMR AFR EMR SEAR WPR Laboratories Worldwide Virus Isolation Laboratory (43) ITD Laboratory (70*) Sequencing Laboratory (26) Global Specialized Laboratory (7) *Includes 16 in process of implementation AFR: African Region AMR: Americas Region EMR: Eastern Mediterranean Region EUR: European Region ITD: Intratypic differentiation SEAR: South Eastern Asia Region WPR: Western Pacific Region World Health Organization

EMRO and AFRO NOT Certified 80% of the World s Children live in Polio-free Regions

Polio Eradication and Endgame Strategy 1. Poliovirus detection & interruption 2. OPV2 withdrawal, IPV introduction, immunization system strengthening 3. Containment & Global Certification 4. Transition Planning

Post-Certification Strategy Goals Purpose: Define how a polio-free world will be sustained Goal 1: Contain Polio Sources Ensure potential sources of poliovirus are properly controlled or removed Goal 2: Protect Populations Immunize populations against unanticipated polio events Goal 3: Detect and Respond Detect any poliovirus introduction and rapidly respond to prevent transmission Goal 4: Manage Effectively and Monitor Ensure ongoing polio functions are embedded in existing or develop new approaches to sustain the goals of polio post-certification 26

Program Risks Reasons for Optimism Routine Immunization SIA Quality Immunity gaps AFP Surveillance missed transmission Environmental Surveillance Mobile and Cross-border populations Security compromised / access Community Trust in Vaccines Containment IPV supply OPV supply Complacency Funding Poor Transition Planning Lowest Number of Cases Declining genetic diversity Expand Environmental Surveillance Risks are known w/ solutions possible Windows of Opportunity in Insecure Areas Evidence Based Communications Technology: GIS, Mobile phones/remote monitoring, baby registries Cost Savings Identified Transition Planning Improving Stronger oversight Country-led efforts and ownership Accountability frameworks

Global Polio Eradication is the largest effort outside of armed conflict in the world. With 20 million volunteers, health workers, lab techs, vaccinators, mobilizers dedicated to the common goal of preventing childhood paralysis. 13 Million Cases of Paralysis Prevented

Every Child Counts! Thank You